Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis, psoriasis, systemic lupus erythematosus, radiographic axial spondyloarthritis (ankylosing spondylitis), idiopathic pulmonary fibrosis, Sjögren’s syndrome and type 1 diabetes.